Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences -- Ignore unavailable to you. Want to Upgrade?

To: Leo Fisher who wrote (88)	4/7/2017 12:14:16 PM
From: axial	Respond to of 250

PROMETIC RECEIVES $9.5 MILLION PURCHASE ORDER FROM MULTINATIONAL CLIENT ' LAVAL, QUEBEC, CANADA, – April 7, 2017 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it has received a $9.5 million purchase order for the supply of affinity resin to an existing client, a global leader in the biopharmaceutical industry. This purchase order is part of an ongoing license and long-term supply agreement already secured with the client. The affinity resin will be manufactured by Prometic at its Isle of Man facility and supplied to the client starting in the second half of 2017 and continuing throughout 2018. Prometic’s client is using the resin for large-scale purification of a therapeutic protein product manufactured in large quantities. Commenting on this latest purchase order, Mr. Pierre Laurin, President and Chief Executive officer of Prometic said: “As much as we place great importance on our internal proprietary bioseparation capabilities to develop, manufacture and commercialize our own impressive portfolio of high value plasma-derived therapeutics, we also continue to work hard to grow our revenues from third party customers”. “This latest PO is evidence of the strength of our corporate relationships”, said Dr. Steve Burton, Prometic Bioseparations’ Chief Executive Officer. “We expect our 2017 bioseparation revenues to be slightly ahead of 2016 and then to nearly double in 2018”.' Jim